阿德利克斯(Ardelyx，股票代码：ARDX)周二盘中股价大涨6.83%，引发市场关注。该公司主要从事开发和商业化同类首创药品，以满足未被满足的医疗需求。
消息面上，花旗银行最新研报维持阿德利克斯的"买入"评级，虽然将目标价从11.00美元小幅下调至10.00美元。这一评级维持可能是推动股价上涨的主要因素，表明华尔街分析师仍对公司前景持积极态度。
值得注意的是，阿德利克斯在生物技术行业中表现突出。当天该行业整体下跌2.63%，而阿德利克斯却逆势上扬。公司核心产品Tenapanor（品牌名IBSRELA和XPHOZAH）在治疗便秘型肠易激综合征（IBS-C）和降低慢性肾病患者血清磷水平方面的应用前景，可能是投资者看好该公司的重要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.